INNOVENT BIO (01801) reported more than 8.2 billion yuan in product revenue for the first half of the year, representing a year-on-year increase of over 55%.

INNOVENT BIO (01801) announced that in the first half of 2026, the company's product revenue exceeded RMB 8.2 billion, representing a year-on-year increase of more than 55%. In the second quarter alone, the product revenue surpassed RMB 4.3 billion, with a year-on-year growth of approximately 60%. This strong performance fully reflects the ongoing effectiveness of the company's "dual-drive" strategy. The comprehensive product line maintains robust growth, with core products such as (Schisandrin injection), (Tocilizumab injection), and (Tremelimumab N01 injection) performing exceptionally well, becoming important drivers of revenue growth. Additionally, the company's leadership advantage in the oncology field continues to solidify, with the market penetration of five newly included tyrosine kinase inhibitors (TKIs) in the National Reimbursement Drug List (NRDL) continuing to rise, accelerating revenue growth. Furthermore, the company has successfully expanded its strategic reach into the commercial field of breast cancer treatment, partnering with Eli Lilly for the commercialization of (Abemaciclib tablets) in mainland China, laying a solid foundation for the company's subsequent breast cancer pipeline research and market expansion. In the first half of 2026, supported by a leading revenue scale and strong growth in a diversified product portfolio, the company continued to solidify its position as a leading biopharmaceutical enterprise in China. Globally, the company is advancing three core innovative assets into Phase III clinical studies and continuously expanding new generation innovative pipelines in oncology, cardiovascular and metabolic (CVM), autoimmune, and ophthalmic fields. Meanwhile, the company has over 20 collaborative projects with multinational pharmaceutical companies including Pfizer, Eli Lilly, Takeda, and Roche, among which are five co-development and co-commercialization (Co-Co) pipelines, with its global innovation capability continuously gaining recognition. Looking ahead, the company will rely on the ongoing expansion of its domestic business and the continuous advancement of its global innovation pipeline to accelerate its international, steadily moving towards the long-term vision of "becoming a world-class biopharmaceutical company."